Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Istodax
Romidepsin is a bicyclic depsipeptide histone deacetylase (HDAC) inhibitor indicated for the treatment of certain types of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). It works by inhibiting HDACs, enzymes that play a role in gene regulation and cell proliferation, leading to cell cycle arrest and apoptosis (programmed cell death) in cancer cells.
For the treatment of certain types of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
Romidepsin can cause serious and potentially fatal cardiac events, including QT interval prolongation, torsades de pointes, and sudden death. Blood counts should be monitored regularly, as romidepsin can cause myelosuppression (decreased production of blood cells). Embryo-fetal toxicity has been observed in animal studies, so romidepsin should not be used during pregnancy.
Outcome:
Increased romidepsin levels and risk of toxicity
Mechanism:
Inhibition of romidepsin metabolism
Outcome:
Decreased romidepsin absorption
Mechanism:
Changes in gastric pH
Outcome:
No clinically significant interaction expected
Mechanism:
None known
Most likely new formulation: Liposomal formulation for improved delivery and reduced toxicity (Year 2025, 60% confidence)
Based on current usage trends and clinical trial data, there is a 75% likelihood of romidepsin being approved for additional indications in hematological malignancies within the next 5 years.
Antineoplastic Agent, Histone Deacetylase (HDAC) Inhibitor
Bicyclic Depsipeptide